REGN Stock Annual Income Statement. Download in Excel
Regeneron Pharmaceuticals Inc.
REGN 
NGS
Sector: Healthcare
Industry: Biotechnology
529.24
USD
7.40
(1.42%)
Previous close: 521.84 Open: 518.25 Bid: 521.0 Ask: 532.0
52 week range
476.49 1,211.20
Mkt Cap: 56,523 M Avg Vol (90 Days): 1,311,297
Last updated: Sunday 15th June 2025
Financials
REGN Income Statement
Annual
| Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | Dec-24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Basic EPS from continuing operations | 6.17 | 8.55 | 11.27 | 22.65 | 19.38 | 32.65 | 76.4 | 40.51 | 37.05 | 40.9 |
| Basic EPS total | 6.17 | 8.55 | 11.27 | 22.65 | 19.38 | 32.65 | 76.4 | 40.51 | 37.05 | 40.9 |
| Basic weighted shares outstanding | 103 M | 105 M | 106 M | 108 M | 109 M | 108 M | 106 M | 107 M | 107 M | 108 M |
| Cost of sales | 242 M | 195 M | 203 M | 254 M | 403 M | 1,120 M | 2,438 M | 1,560 M | 1,816 M | 1,971 M |
| Depreciation | 75 M | 105 M | 145 M | |||||||
| DepreciationAndAmortization | 75 M | 105 M | 145 M | |||||||
| Diluted EPS total | 5.52 | 7.7 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 |
| Diluted normalized net income/share | 5.52 | 7.7 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 |
| Diluted weighted shares outstanding | 115 M | 116 M | 116 M | 115 M | 115 M | 115 M | 112 M | 114 M | 114 M | 115 M |
| GainOnSaleOfSecurity | 8 M | |||||||||
| GeneralAndAdministrativeExpense | 839 M | 1,178 M | 1,320 M | 1,556 M | 1,342 M | 1,346 M | 1,825 M | 2,116 M | 2,631 M | 2,954 M |
| Gross operating profit | 3,862 M | 4,666 M | 5,670 M | 6,457 M | 6,155 M | 7,377 M | 13,634 M | 10,613 M | 13,117 M | 12,232 M |
| Income before tax | 1,225 M | 1,330 M | 2,079 M | 2,554 M | 2,429 M | 3,810 M | 9,326 M | 4,859 M | 4,199 M | 4,780 M |
| Income taxes | 589 M | 434 M | 880 M | 109 M | 313 M | 297 M | 1,251 M | 520 M | 246 M | 367 M |
| Interest income | -14 M | -7 M | -25 M | |||||||
| InterestExpenseNonOperating | 14 M | 25 M | 28 M | 30 M | 57 M | 57 M | 59 M | 73 M | 55 M | |
| InterestIncomeOperating | 46 M | |||||||||
| MiscOtherSpecialCharges | -13 M | 6 M | 24 M | 47 M | 250 M | 291 M | 436 M | 179 M | 225 M | 844 M |
| Net income from total operations | 636 M | 896 M | 1,199 M | 2,444 M | 2,116 M | 3,513 M | 8,075 M | 4,338 M | 3,954 M | 4,413 M |
| NetIncomeCommonStockholders | 938 M | 1,106 M | 1,199 M | 2,444 M | 2,478 M | 3,513 M | 8,171 M | 4,338 M | 3,954 M | 4,413 M |
| NetIncomeContinuousOperations | 636 M | 896 M | 1,199 M | 2,444 M | 2,116 M | 3,513 M | 8,075 M | 4,338 M | 3,954 M | 4,413 M |
| NetNonOperatingInterestIncomeExpense | -14 M | -7 M | -25 M | -28 M | -30 M | -57 M | -57 M | -101 M | -45 M | -46 M |
| Normalized income | 796 M | 864 M | 1,351 M | 2,017 M | 1,919 M | 3,010 M | ||||
| Operating income | 1,252 M | 1,331 M | 2,080 M | 2,534 M | 2,210 M | 3,577 M | 8,947 M | 4,739 M | 4,047 M | 3,991 M |
| Operating income before depreciation (EBITDA) | 1,300 M | 1,435 M | 2,249 M | 2,730 M | 2,670 M | 4,103 M | 9,669 M | 5,260 M | 4,693 M | 5,318 M |
| OperatingExpense | 2,459 M | 3,230 M | 3,396 M | 3,742 M | 3,583 M | 3,801 M | 4,639 M | 5,619 M | 7,068 M | 8,140 M |
| Other income net | 13 M | -6 M | -24 M | -47 M | -249 M | -291 M | -436 M | -236 M | -225 M | -844 M |
| OtherGandA | 839 M | 1,178 M | 1,320 M | 1,556 M | 1,342 M | 1,346 M | 1,825 M | 2,116 M | 2,631 M | 2,954 M |
| OtherOperatingExpenses | -60 M | -46 M | -49 M | -51 M | -209 M | -280 M | -46 M | -90 M | -2 M | 53 M |
| RentAndLandingFees | 15 M | 17 M | 4 M | 5 M | ||||||
| Research & development expense | 1,621 M | 2,052 M | 2,075 M | 2,186 M | 2,450 M | 2,735 M | 2,860 M | 3,593 M | 4,439 M | 5,132 M |
| ResearchExpense | 1,621 M | 2,052 M | 2,075 M | 2,186 M | 2,450 M | 2,735 M | 2,860 M | 3,593 M | 4,439 M | 5,132 M |
| Revenue per share | 14 M | 14 M | 14 M | 930 M | 1,053 M | 1,163 M | ||||
| SalariesAndWages | 459 M | |||||||||
| Selling Gen & administrative expense | 839 M | 1,178 M | 1,320 M | 1,556 M | 1,342 M | 1,346 M | 1,825 M | 2,116 M | 2,631 M | 2,954 M |
| Total Income available for interest expense (EBIT) | 1,225 M | 1,330 M | 2,104 M | 2,582 M | 2,459 M | 3,867 M | 9,383 M | 4,918 M | 4,272 M | 4,835 M |
| Total common shares outstanding | 210 M | 212 M | 215 M | 219 M | 220 M | 107 M | 109 M | 109 M | 110 M | 109 M |
| Total net income | 636 M | 896 M | 1,199 M | 2,444 M | 2,116 M | 3,513 M | 8,075 M | 4,338 M | 3,954 M | 4,413 M |
| Total ordinary shares | 106 M | 106 M | 106 M | 106 M | 106 M | 106 M | 106 M | 106 M | 106 M | 106 M |
| Total revenues | 4,104 M | 4,860 M | 5,872 M | 6,711 M | 6,558 M | 8,497 M | 16,072 M | 12,173 M | 13,117 M | 14,202 M |
| TotalExpenses | 2,701 M | 3,425 M | 3,598 M | 3,996 M | 3,986 M | 4,429 M | 6,413 M | 7,179 M | 7,068 M | 10,110 M |
| TotalRevenue | 4,104 M | 4,860 M | 5,872 M | 6,711 M | 6,558 M | 8,497 M | 16,072 M | 12,173 M | 13,117 M | 14,202 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.